🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Manchester
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Manchester, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2853 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Sep 2026, 03:15 UTC
2853
Studies in scope
industry-sponsored, all four open statuses
1386
Recruiting now
open to new participants
545
Lead sponsors
across recruiting studies
Top sites
London 2010 Manchester 670 Birmingham 470 Glasgow 437 Cambridge 418
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca73 Merck Sharp & Dohme LLC39 Janssen Research & Development, LLC28 Hoffmann-La Roche25 Eli Lilly and Company17
Site city
London2010 Manchester670 Birmingham470 Glasgow437 Cambridge418
All 425 cities
Target enrolment
to

Trials with a site in Manchester

670 of 2853 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,264
Aberdeen, Dundee, Huddersfield, Leeds, Manchester, Northwood, Sheffield, Wolverhampton
2023-12-21
Active, closed
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.
Phase 3
200
London, Manchester, Nottingham
2023-12-20
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566CLL/SLL
Ascentage Pharma Group Inc.
Phase 3
400
Birmingham, Bournemouth, Liverpool, London, Manchester, Stoke-on-Trent, Swansea, West Bromwich
2023-12-20
Recruiting
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT06154252Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy
Cabaletta Bio
Phase 2/3
74
London, Manchester, Salford
2023-12-20
Recruiting
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Phase 3
120
Birmingham, Leeds, London, Manchester, Oxford
2023-12-20
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 3
1,145
Aberdeen, Cambridge, Hampshire, Leeds, London, Manchester, Metropolitan Borough of Wirral, Northwood
2023-12-14
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intellia Therapeutics
Phase 3
1,200
Birmingham, Cardiff, Glasgow, Hexham, Liverpool, London, Manchester
2023-12-13
Active, closed
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
NCT07116889Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Generate Biomedicines
Phase 1
156
London, Manchester, Merthyr Tydfil
2023-12-12
Active, closed
A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
NCT06149403MPS-IH (Hurler Syndrome)
Orchard Therapeutics
Phase 3
41
Manchester
2023-12-11
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
East Sussex, Derby, London, Truro, Glasgow, Manchester
2023-12-06
Recruiting
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca
Phase 1/2
564
Cambridge, Leeds, London, Manchester
2023-12-05
Recruiting
Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery
NCT06246136Open Angle Glaucoma
Elios Vision, Inc.
Not applicable
194
East Grinstead, Edinburgh, Guildford, London, Manchester
2023-12-05
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Cambridge, Edgbaston, Glasgow, Scotland, London, Manchester, Sutton
2023-12-04
Active, closed
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
NCT06150183Advanced Malignant Solid Tumor
BioNTech SE
Phase 1
41
London, Manchester, Newcastle
2023-11-30
Recruiting
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
NCT06166056Bronchiectasis
Chiesi Farmaceutici S.p.A.
Phase 1/2
45
Cambridge, Dundee, Edinburgh, Glasgow, Leeds, London, Manchester, Southampton
2023-11-29
Active, closed
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 1
127
Barnsley, Blackpool, Cambridge, Cannock, London, Manchester, West Yorkshire
2023-11-27
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Aberdeen, Birmingham, Cambridge, Glasgow, Guildford, London, Manchester, Newcastle upon Tyne
2023-11-21
Recruiting
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
NCT06173518Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Autolus Limited
Phase 1
30
London, Manchester, Newcastle upon Tyne
2023-11-16
Recruiting
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT05319353Cytomegalovirus (CMV)
Takeda
Phase 3
80
London, Manchester, Nottingham, Birmingham
2023-11-13
Recruiting
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
NCT06193902Tumor, Solid
Leucid Bio
Phase 1/2
17
London, Manchester
2023-11-13
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
556
London, Sutton, Manchester, Metropolitan Borough of Wirral
2023-11-12
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
AstraZeneca
Phase 3
863
Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton
2023-11-09
Active, closed
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
NCT06046820Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
Inozyme Pharma
Phase 3
27
Manchester
2023-11-05
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626Metastatic Breast Cancer
LeonaBio
Phase 3
600
Cardiff, Harlow, Leeds, London, Manchester, Milton Keynes, Nottingham, Stockton-on-Tees
2023-10-31
Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease
United Therapeutics
Phase 3
698
Birmingham, Cambridge, Edinburgh, London, Manchester, Perth
2023-10-30
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
Summit Therapeutics
Phase 3
1,600
Leeds, London, Manchester
2023-10-26
Recruiting
ZNN Bactiguard Retrograde Femoral Nails PMCF Study
NCT05276674Femoral Fracture
Zimmer Biomet
Observational
100
Leeds, Manchester, Stockport
2023-10-23
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
BeOne Medicines
Phase 2
114
Bournemouth, Glasgow, Headington, Inverness, Leeds, London, Manchester, Plymouth
2023-10-23
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936Lymphoma
Hoffmann-La Roche
Phase 3
182
Glasgow, Lincoln, London, Manchester, Oxford, Plymouth
2023-10-22
Active, closed
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333Congestive Heart Failure
AskBio Inc
Phase 2
150
Manchester, Leeds, Cardiff, Glasgow, London
2023-10-20
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim
Phase 2
204
Leicester, London, Manchester, Newcastle upon Tyne
2023-10-13
Active, closed
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
NCT06109649Vitiligo
Clinuvel, Inc.
Phase 3
200
London, Manchester
2023-10-11
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
Novartis Pharmaceuticals
Phase 3
106
Belfast, Cardiff, London, Manchester, Salford
2023-10-02
Active, closed
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT05936359Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
160
London, Manchester, Oxford
2023-09-25
Active, closed
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT06088290Leiomyosarcoma
PharmaMar
Phase 3
469
Birmingham, Cambridge, Liverpool, London, Manchester, Oxford
2023-09-21
By invitation
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
NCT06075537Mucopolysaccharidosis II
Denali Therapeutics Inc.
Phase 2/3
99
Birmingham, London, Manchester
2023-09-20
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals
Phase 3
410
Cambridge, Edinburgh, Birmingham, London, Manchester
2023-09-18
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171Glomerulonephritis Rapidly Progressive
Alentis Therapeutics AG
Phase 2
80
Birmingham, Cambridge, Liverpool, London, Manchester, Preston
2023-09-07
Active, closed
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
NCT06041269Rheumatoid Arthritis
AnaptysBio, Inc.
Phase 2
420
London, Manchester
2023-08-31
Active, closed
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
NCT06254482Huntington Disease
Novartis Pharmaceuticals
Phase 2
144
Birmingham, Cardiff, London, Manchester
2023-08-25
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
GlaxoSmithKline
Phase 3
892
Birmingham, Chelmsford, Cheltenham, Edinburgh, Hull, Leeds West Yorkshire, London, Manchester
2023-08-01
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.
Phase 2
220
Barnet, London, Manchester, Nottingham
2023-07-31
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Incyte Corporation
Phase 1
570
Cambridge, London, Manchester, Newcastle upon Tyne
2023-07-24
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
Merck Sharp & Dohme LLC
Phase 3
1,089
Bristol, Cambridge, Cringleford, London, Edinburgh, Oxford, Leeds, Manchester
2023-07-19
Active, closed
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Phase 3
100
Peterborough, Manchester, Southampton
2023-07-11
By invitation
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
NCT05777993Pyruvate Kinase Deficiency, Anemia, Hemolytic, Sickle Cell Disease, Thalassemia
Agios Pharmaceuticals, Inc.
Phase 4
59
Manchester
2023-07-06
Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1/2
230
Glasgow, London, Manchester, Newcastle upon Tyne, Oxford
2023-07-06
Active, closed
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510Non Small Cell Lung Cancer
OncoC4, Inc.
Phase 3
630
Birmingham, Cambridge, Exeter, Leicester, London, Middlesbrough, Torquay, Manchester
2023-06-28
Active, closed
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
NCT05601752Ovarian Cancer
USWM CT, LLC
Phase 2
66
London, Manchester
2023-06-26
Active, closed
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
NCT05734196Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency
Inozyme Pharma
Phase 1
16
Manchester
2023-06-25
Recruiting
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
NCT05967143Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
Sirtex Medical
Observational
845
Manchester, London
2023-06-19
Recruiting
A Retrospective Study to Characterize Participants With Propionic Acidemia
NCT05769621Propionic Acidemia
ModernaTX, Inc.
Observational
60
Kirkcaldy, Manchester, City of London, Birmingham
2023-06-16
Active, closed
A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
NCT05898620Rett Syndrome
Neurogene Inc.
Phase 3
33
Edinburgh, Manchester
2023-06-13
Active, closed
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
ArriVent BioPharma, Inc.
Phase 3
398
Guildford, Bebington, London, Manchester, Sutton
2023-06-01
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
Amgen
Phase 3
509
London, Manchester
2023-05-31
Active, closed
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
NCT05809531C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis
Apellis Pharmaceuticals, Inc.
Phase 3
100
London, Manchester, Nottingham
2023-05-29
Recruiting
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567Ulcerative Colitis, Crohn's Disease
Takeda
Phase 3
240
London, Cardiff, Birmingham, Manchester
2023-05-16
Recruiting
Multicenter Glaucoma Study Investigating Standalone Canaloplasty
NCT05786196Primary Open Angle Glaucoma
Nova Eye, Inc.
Not applicable
86
Edinburgh, Liverpool, Manchester
2023-05-09
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Gilead Sciences
Phase 3
654
London, Manchester, Nottingham
2023-05-08
Active, closed
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
NCT05552469Myeloid Diseases
Novartis Pharmaceuticals
Phase 1
71
Cardiff, London, Manchester
2023-05-08
Active, closed
Phase III Study of AK112 for NSCLC Patients
NCT06396065Non-Squamous Non-small Cell Lung Cancer
Summit Therapeutics
Phase 3
420
London, Manchester
2023-05-04
Active, closed
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
NCT05876754Cholangiocarcinoma
Servier Affaires Médicales
Phase 3
299
Birmingham, Glasgow, London, Manchester, Newcastle upon Tyne
2023-05-03
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
NCT05800665Advanced Prostate Cancer, Metastatic Prostate Cancer
Genentech, Inc.
Phase 1
210
Cambridge, Leicester, Manchester, Sutton
2023-05-02
Active, closed
FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
NCT05466799Locally Advanced Pancreatic Cancer
OncoSil Medical Limited
Phase 2
88
London, Manchester, Newcastle upon Tyne, Southampton
2023-04-26
Active, closed
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer
AstraZeneca
Phase 2
294
Cambridge, London, Manchester
2023-04-24
Active, closed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2
199
London, Manchester
2023-04-21
Recruiting
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
NCT05685173B-cell Non-Hodgkins Lymphoma (B-NHL)
Regeneron Pharmaceuticals
Phase 1
107
Truro, Southampton, Edinburgh, Manchester
2023-04-20
Active, closed
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
NCT05692180Asthma
AstraZeneca
Phase 3
94
London, Manchester
2023-04-05
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
Leeds, London, Manchester
2023-04-04
Recruiting
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT05650632Multiple Myeloma
AbbVie
Phase 1
210
London, Manchester
2023-03-21
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 3
520
Cheltenham, London, Northwood, Southampton, Sutton, Manchester, Swansea
2023-03-15
Active, closed
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
NCT05705349HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
537
Bristol, London, Manchester
2023-03-08
Active, closed
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623Advanced Breast Cancer
Pfizer
Phase 3
624
London, Blackburn, Glasgow, Manchester
2023-03-03
Recruiting
Magseed Pro(R)/ Sentimag(R) Gen3
NCT05142787Breast Cancer
Endomagnetics Ltd.
Not applicable
224
London, Manchester
2023-03-02
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Day One Biopharmaceuticals, Inc.
Phase 3
418
Birmingham, Leeds, Liverpool, Manchester, Newcastle upon Tyne, Oxford, Southampton, Belfast
2023-02-27
Active, closed
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 1/2
26
Cambridge, Glasgow, London, Manchester, Penarth, Southampton
2023-02-27
Recruiting
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
Fore Biotherapeutics
Phase 2
254
Manchester, London
2023-02-21
Active, closed
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476Allergy, Peanut
DBV Technologies
Phase 3
600
London, Manchester, Sheffield, Southampton
2023-02-21
Active, closed
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
NCT05797896Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration
Complement Therapeutics
Observational
250
Belfast, Bradford, Frimley, Gloucester, Liverpool, London, Manchester, Newcastle
2023-02-07
Active, closed
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
NCT05748600Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
Areteia Therapeutics
Phase 3
600
Bellshill, Birmingham, Bollington, Chorley, Enfield, Liverpool, London, Manchester
2023-01-30
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562H3 K27M, Glioma
Jazz Pharmaceuticals
Phase 3
510
Cambridge, Glasgow, Liverpool, Manchester, Sutton, Newcastle upon Tyne, Leeds, London
2023-01-23
Active, closed
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291Melanoma
Regeneron Pharmaceuticals
Phase 3
1,564
Exeter, Edinburgh, Bristol, Sutton, Coventry, London, Manchester, Taunton
2023-01-16
Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Eli Lilly and Company
Phase 1
677
Manchester, Sheffield
2023-01-12
Recruiting
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
NCT06198712Sickle Cell Disease
Forma Therapeutics, Inc.
Phase 2
95
London, Manchester
2023-01-12
Recruiting
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Ellipses Pharma
Phase 1/2
95
London, Manchester, Liverpool
2023-01-11
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
284
Nottingham, Cannock, London, Manchester, Newcastle upon Tyne
2023-01-02
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Aberdeen, Cambridge, Cardiff, Cheltenham, Edinburgh, London, Manchester, Middlesbrough
2022-12-29
Recruiting
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT05549297Advanced Melanoma
Immunocore Ltd
Phase 3
540
Cambridge, Manchester, Birmingham, Leeds, London, Middlesex, Sutton
2022-12-19
Active, closed
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc.
Phase 3
885
Woodhurst, Huddersfield, Blackpool, Hull, Liskeard, Manchester, Newquay, Poole
2022-12-13
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654Triple Negative Breast Cancer
Gilead Sciences
Phase 3
1,514
Cottingham, Edgbaston, Liverpool, London, Manchester, Northwood, Taunton, York
2022-12-12
Active, closed
OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness
NCT05677763Respiratory Tract Infections, Wheezing Lower Respiratory Illness
OM Pharma SA
Phase 4
525
Brighton, Manchester, Nottingham, Edinburgh, London
2022-12-12
Active, closed
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
NCT05529316Advanced Melanoma
Agenus Inc.
Phase 2
150
London, Manchester, Middlesex
2022-12-12
Recruiting
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
NCT05611801Hemophilia A, Hemophilia B
Pfizer
Phase 3
100
Newcastle upon Tyne, Birmingham, London, Manchester
2022-12-09
Active, closed
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886Breast Cancer
Celcuity Inc
Phase 3
701
Bath, Cardiff, London, Manchester, Nottingham, Sutton
2022-12-08
By invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Bellshill, Edgbaston, Manchester, Cardiff, Hampstead, Liverpool, London
2022-11-30
Active, closed
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585Breast Cancer
AstraZeneca
Phase 3
1,174
Cambridge, Cardiff, Edinburgh, Greater London, London, Londonderry, Manchester, Newcastle upon Tyne
2022-11-28
Recruiting
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283Chronic Kidney Disease, Proteinuria, Children
Bayer
Phase 3
100
London, Manchester, Nottingham, Glasgow
2022-11-08
Active, closed
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3
68
Manchester
2022-11-01
Active, closed
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
NCT05434156Healthy Volunteers, Major Depressive Disorder, Depression
Eleusis Therapeutics
Phase 1/2
84
Liverpool, Manchester
2022-10-27
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Newcastle upon Tyne, Glasgow, Sutton, Bristol, Cambridge, Leeds, London, Manchester
2022-10-24
Rows per page Showing 301–400 of 670
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-uk/city/manchester?page=4

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,853 studies in total at the last sync on 24 Sep 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 670 of those studies with a site in Manchester.

How many clinical trials are recruiting in Manchester?

336 of the 670 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:15 UTC sync. A further 8 have not yet opened recruitment, 314 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.